BIEL - BioElectronics Corporation
| Previous Close | 0.0007 |
| Open | 0.0006 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0006 - 0.0007 |
| 52 Week Range | 0.0005 - 0.0025 |
| Volume | 82,243,022 |
| Avg. Volume | 45,381,248 |
| Market Cap | 15.388M |
| Beta (3Y Monthly) | 2.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
BioElectronics Founder and CEO Andrew J. Whelan Has Died Suddenly
FREDERICK, MD, Oct. 07, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corp. (OTCPK: BIEL) is sad to announce that its founder and CEO, Andrew J. Whelan, died suddenly last night.
- GlobeNewswire
Update: BioElectronics Announces Publication of a Study of the ActiPatch Medical Device as an Effective Long-Term Treatment for Chronic Pain
FREDERICK, MD, Oct. 02, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased.
- GlobeNewswire
BioElectronics Announces Publication of a Study of the ActiPatch Medical Device as an Effective Long-Term Treatment for Chronic Pain
FREDERICK, MD, Oct. 02, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased.
- GlobeNewswire
BioElectronics Files FDA 510(k) Application for Musculoskeletal Pain Complaints; Clinical Data Demonstrates Superior Drug Free Pain Relief to Prescription Strength NSAID Drug
FREDERICK, MD, Aug. 20, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, is pleased to announce that it has filed a 510(k), Premarket.
- ACCESSWIRE
The Stock Day Podcast Hosts BioElectronics' to Discuss Its New Technology To Mitigate Opioid Use
PHOENIX, AZ / ACCESSWIRE / July 10, 2019 / The Stock Day Podcast welcomed BioElectronics Corporation (BIEL) (“the Company”), a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices. Vice President of Sales, Keith Nalepka, joined Stock Day host Everett Jolly. Jolly began the interview by asking Nalepka to update listeners on the Company’s recent FDA approval for the treatment of postoperative pain.
- GlobeNewswire
BioElectronics Announces FDA Market Clearance for Its Non-Opioid Postoperative Pain Therapy
FREDERICK, MD, July 01, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased.
- GlobeNewswire
BioElectronics Announces Publication of Study Verifying the Effectiveness of Its ActiPatch Medical Device on Chronic Pain
FREDERICK, MD, June 03, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased.
- GlobeNewswire
BioElectronics Announces Withdrawal and Planned Resubmission of 510(k) for General Musculoskeletal Pain
FREDERICK, MD, May 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, announced today that it has voluntarily withdrawn its 510(k) application for “over-the-counter adjunctive treatment of musculoskeletal pain in women” to the U.S. Food and Drug Administration (FDA), due to the availability of data that can support the more valuable, non-gender specific indications of use. The ActiPatch is FDA-cleared for over-the-counter adjunctive treatment of pain from knee osteoarthritis (25 million Americans) and plantar fasciitis (2 million Americans annually). The 510(k) that was submitted in February 2019 was to seek expanded clearance on treatment of general musculoskeletal pain in women and included robust clinical evidence on women from three ActiPatch clinical studies: knee osteoarthritis, plantar fasciitis and low back pain.
- GlobeNewswire
BioElectronics Responds to FDA’s 510(k) Additional Information Requests for its Musculoskeletal Pain Relief and Postoperative Pain Applications
FREDERICK, MD, April 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com announced that the Company has submitted its response to the U.S. Food and Drug Administration’s (FDA) request for additional information on its ActiPatch® 510(k) market clearance application for “treatment of musculoskeletal pain in women”. Additionally, the Company has requested a conference call with the FDA to seek clarification on additional information requested on the RecoveryRx® 510(k) market application for “treatment of postoperative pain”. The FDA’s additional information requested on the musculoskeletal 510(k) was for the submission of women’s clinical performance data from the Company’s clinical studies on knee osteoarthritis, plantar fasciitis and low back pain.
- PR Newswire
Northwest Specialty Hospital Now Offering Electroceutical Alternative To Opioids In Clinical Practice
POST FALLS, Idaho, March 14, 2019 /PRNewswire/ -- Northwest Specialty Hospital is proud to announce that they are offering electroceutical devices as an alternative to opioid medication for pain management in conjunction with RiversEdge Orthopedics, Axis Spine and Bioelectronics Corporation (OTC PINK: BIEL). Post-surgical pain is reported by approximately 80% of patients following an operation and opioids are a common treatment option chosen by patients suffering from post-surgical pain. In light of the growing epidemic of opioid abuse, dependence and overdose in the United States, exploration of alternative therapeutic options to reduce potential exposure to opioids, Northwest Specialty Hospital feels compelled to explore non-pharmacologic, FDA approved alternatives to opioids. As such, they are engaged in discussions with Bioelectronics Corporation about the clinical results of their line of bioelectronics devices and were intrigued by both the science and the results behind these bioelectronics devices.
- GlobeNewswire
BioElectronics Announces Back Pain Clinical Study with Leading Australian Pain Center
Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back Pain FREDERICK, MD, March 08, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation.
- GlobeNewswire
BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain
FREDERICK, MD, Feb. 12, 2019 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two Traditional 510(k) Premarket.
- GlobeNewswire
BioElectronics President’s Response to Stock Price Decline
While we were all disappointed by the dramatic drop in the stock price, it hasn’t had an impact on the Company’s operations. Back pain and post-operative pain are the major uses of opioid. BioElectronics products work when nothing else does because it is The New Technology for Pain Relief.
- GlobeNewswire
BioElectronics Announces FDA Market Clearance Update
FREDERICK, MD, Nov. 27, 2018 -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced that the U.S. Food.
- GlobeNewswire
BioElectronics Signs a Five Country Additional Distribution Agreement with Mundipharma Pty Limited, South East Asia
FREDERICK, MD, Nov. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that Mundipharma Pty Limited, has added the ActiPatch® Musculoskeletal Pain Therapy medical device to its pain management portfolio by acquiring the distribution rights in South East Asia, for Singapore, Malaysia, Thailand, Indonesia and the Philippines. “Mundipharma is adding five additional countries to their Australia and New Zealand ActiPatch sales program.
- ACCESSWIRE
BioElectronics Discusses Advancing the Electroceuticals Market
PHOENIX, AZ/ ACCESSWIRE / November 13th, 2018 / BioElectronics Corporation (OTC PINK: BIEL), is a maker of advanced medical devices. Jolly began the interview by asking Nalepka to give an update on his progress in advancing the electroceutical market. Nalepka reported how we are moving forward with CVS pharmacies, B. Braun's same day hip and knee replacements program, the Veterans Administration, hospices and nursing sales, and the expansion of its territorial distribution relationship with Mundipharma, International Limited.